A phase II, single arm, open label, multicentre study of CP-751,871 in combination with docetaxel and prednisone in patients with progressive hormone refractory prostate cancer

Trial Profile

A phase II, single arm, open label, multicentre study of CP-751,871 in combination with docetaxel and prednisone in patients with progressive hormone refractory prostate cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2006

At a glance

  • Drugs Figitumumab (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top